Ketamine Therapy for Suicidal Ideation: What We Know

Suicidal ideation does not wait for the next available appointment. It erupts in the middle of a school week, at 2 a.m. On a Sunday, in the hour after a breakup or a job loss, after months of sleeplessness or a lifetime of trauma. When people and their families ask about ketamine therapy in this context, the underlying hope is straightforward: is there something that can quiet the mind quickly enough to keep me alive while longer term treatments take hold? Over the last fifteen years, the answer has been moving from possibility to measured, qualified yes.

This is a summary of what the research supports, where the limitations sit, and how clinics that work with suicidal patients aim to use ketamine therapy responsibly. It also weaves in clinical realities, including when ketamine may not be the right tool and why integration with psychotherapy matters.

What ketamine is, and what is actually approved

Ketamine is an anesthetic developed in the 1960s, long used in operating rooms and emergency departments because it preserves breathing and blood pressure while allowing painful procedures. At lower doses, it has rapid antidepressant effects. There are two broad ways it is used for mental health:

Racemic ketamine, delivered intravenously, intramuscularly, or orally, is generic and prescribed off label for depression and suicidal ideation in many clinics. Esketamine, the S-enantiomer, is an FDA-approved intranasal medication used in certified clinics under a risk management program. In the United States it is approved for treatment resistant depression and for depressive symptoms in major depressive disorder with acute suicidal ideation or behavior, as an adjunct to standard of care and with careful monitoring.

That distinction matters for access and insurance. Esketamine’s approval includes use in people who are hospitalized for a suicidal crisis, with dosing in a clinic and observation afterward. Intravenous racemic ketamine remains off label, even though the clinical evidence is strong for many patients. Both share a core feature that makes them relevant in crisis care: their antidepressant and anti-suicidal effects can begin within hours, not weeks.

What the evidence shows about suicidal ideation

The landmark finding was simple and startling. A single intravenous infusion of racemic ketamine at 0.5 mg per kilogram, administered over about 40 minutes, reduced suicidal ideation within 4 to 24 hours in many participants. This was repeatedly demonstrated across randomized controlled trials and confirmed in meta-analyses. Suicidal thoughts commonly fell by a clinically meaningful amount on standardized scales such as the Scale for Suicide Ideation or items within the Montgomery–Åsberg Depression Rating Scale. In head-to-head comparisons with saline placebo or midazolam, ketamine produced a larger and faster drop in ideation.

Durability is modest with a single dose. The strongest effects tend to peak in the first 24 to 72 hours and then fade across 3 to 7 days for many people. A course of several infusions, often six over three weeks, extends the benefit in a good number of patients into the range of weeks to a few months. With maintenance dosing spaced out every 2 to 6 weeks, some patients maintain gains longer, though maintenance needs vary widely.

Esketamine’s trials in hospitalized patients with acute suicidality observed significant reductions in depressive symptoms within 24 hours when esketamine was added to standard care that included medications and psychotherapy. Measured specifically on clinician ratings of suicidality, the signal was present in some analyses and weaker in others, likely because all groups received intensive support. Clinically, many hospital teams now use esketamine to create a rapid easing of pressure while safety plans, sleep restoration, and follow-up therapies are put in motion.

A few practical takeaways emerge from the data and day-to-day experience:

The anti-suicidal effect is not solely a byproduct of mood improvement. Many patients report that the sense of trapped urgency softens first, even before their baseline mood shifts. People with severe insomnia and agitation often notice sleep and rumination improve early, which likely contributes to the drop in suicidal intensity. The response is probabilistic, not guaranteed. In pooled analyses, effect sizes for suicidal ideation are in the moderate to large range, but a clear minority of patients do not respond meaningfully.

How it might work in the brain and body

Mechanism talk tends to slide into jargon, but a few points are worth knowing because they guide practical decisions. Ketamine blocks the NMDA receptor, which tilts the balance of glutamate signaling in a way that increases AMPA receptor throughput. That surge appears to stimulate brain derived neurotrophic factor and downstream pathways that promote synaptogenesis. In plain English, circuits involved in mood, attention, and threat detection seem to sprout new connections, and those connections may support different thought patterns and behavioral flexibility.

Anti-inflammatory effects have also been observed, which fits clinical observations in some trauma and PTSD therapy populations where systemic inflammation is part of the picture. The dissociative experience that often occurs during dosing tracks with some aspects of response, but it is not a perfect predictor. People who have milder perceptual changes can still do well, while others with strong dissociation do not gain sustained benefit. Benzodiazepines and, possibly, very high doses of lamotrigine appear to blunt the antidepressant effect in some patients by altering glutamate dynamics. That is one reason prescribers often trim or space benzos during ketamine therapy if it is safe to do so.

Who benefits most, and where caution is warranted

Most clinics reserve ketamine therapy for patients with major depressive episodes where suicidal ideation is a central concern despite adequate trials of first line treatments. Some patients have unipolar depression. Others have bipolar depression, PTSD, or trauma related symptoms. Comorbidity is the rule. In carefully selected patients, ketamine therapy can be a bridge out of a crisis and into work that endures, including EMDR therapy, trauma therapy, and structured PTSD therapy. When people can sleep, stop rehearsing plans, and feel even a small return of hope, they are far more able to engage in that work.

Caution is essential in several groups:

Active psychosis or a strong history of psychotic disorders raises the risk of symptom exacerbation. A few patients with mood plus psychotic features still do well, but this calls for tight monitoring and close collaboration with the treating psychiatrist. Uncontrolled hypertension, significant cardiovascular disease, or recent aneurysm increase medical risk because ketamine can transiently raise blood pressure and heart rate. With medical clearance and dose adjustments, some safely proceed. Ongoing substance use disorders complicate care. Ketamine has abuse potential. Clinics screen for this, include accountability measures, and decline home ketamine prescriptions in patients with high risk for misuse. Pregnancy and breastfeeding lack strong safety data for repeated psychiatric dosing. Most programs avoid ketamine in pregnancy unless the clinical calculus clearly favors it and obstetric partners are engaged. Adolescents and young adults have emerging evidence suggesting efficacy similar to adults, but require family involvement, developmentally attuned psychotherapy, and extra attention to school and social stressors. Data in children are limited.

What a safe protocol looks like in real life

The picture in a clinic is neither a psychedelic spa day nor an impersonal infusion bay. It is structured, medical, and therapeutic. There is preparation, dosing, and integration.

Before the first session, patients complete a thorough evaluation that includes medical history, medications, substance use, trauma history, and a direct assessment of suicidal thoughts, past attempts, and current intent and capability. We align on a safety plan. If someone is at imminent risk, we route to a higher level of care first. We review consent in plain language: expected benefits, common side effects like nausea and dissociation, rare risks such as significant blood pressure spikes, and the reality that results vary.

On dosing day, patients arrive fasting or with a light snack, depending on route of administration. Vitals are checked, and an IV line is started if using intravenous dosing. We confirm that a trusted ride is set up for afterward. The room is quiet, with dimmable light and blankets. https://www.canyonpassages.com/about Headphones with calming music help some patients, while others prefer silence. The clinician sets a frame: you may drift, your thoughts may wander, you are safe, we are here, and you can speak up at any time.

Infusions typically run 40 minutes for 0.5 mg per kilogram, although some protocols start slightly lower or go slightly higher across visits if needed. Intramuscular dosing can be helpful in clinics without infusion capability. Esketamine is administered in a certified setting with two hours of observation afterward, per regulation. During dosing, blood pressure and heart rate are monitored periodically. A clinician remains present or immediately available, not simply within earshot.

What patients feel varies. Many describe a softening of boundaries and a slowing of mental noise. Some notice memories float up without their usual charge. A smaller subset becomes anxious as control loosens. Skilled reassurance, guided breathing, and occasional dose adjustments usually resolve this. If nausea occurs, antiemetics help. If blood pressure climbs significantly, pausing or reducing the dose and using antihypertensive medication is standard.

After the acute effects fade, we spend time integrating. We ask concrete questions. What did you notice about your thoughts? What felt easier? What seemed to matter less? We link those observations to goals and to psychotherapy. For a person engaged in EMDR therapy, for example, the window after ketamine can be a fertile time to reprocess a target memory with less overwhelm. For someone in couples therapy focused on reducing conflict cycles, a session within a few days of ketamine may allow perspective taking that was not accessible before.

A short checklist for getting ready

Clarify goals in writing, including what “safer” looks like day by day. Review medications with your prescriber, especially benzodiazepines, stimulants, and mood stabilizers. Set up transportation and a supportive presence at home for the first evening. Plan light food, hydration, and comfortable clothing. Agree on communication with your therapist so integration can start within a week.

Measuring progress beyond a number on a scale

Clinicians use tools like the Columbia Suicide Severity Rating Scale, the Beck Scale for Suicide Ideation, and single items such as item 9 on the PHQ 9 to track suicidal thoughts. These matter, but we also watch for practical signals. Are you sleeping more than five or six hours, or at least waking less frequently in panic? Are you deleting saved means or steps toward a plan from your phone or notes? Are you willing to let a partner or friend hold the medications or car keys for a few days? Are showers, meals, and short walks returning?

It is common to see an early drop in the intensity and frequency of suicidal images and rehearsals, paired with longer pauses between those thoughts. That is not the same as being out of danger. We continue means restriction, daily check ins, and therapy appointments, and we adjust other medications as needed. Ketamine is a lever that creates room to move, not the entire lift.

Side effects, risks, and drug interactions you should know about

Short term side effects are usually manageable. Dissociation and perceptual changes are almost expected during dosing and typically resolve within 1 to 2 hours. Nausea, mild headache, dizziness, and a sense of fatigue for the rest of the day are common. Transient blood pressure and heart rate increases occur. Anxiety sometimes spikes if the experience feels unfamiliar or if past trauma gets stirred; preparation helps reduce this.

Longer term risks rise with high frequency or non medical use and include urinary symptoms such as urgency and cystitis, and potential liver enzyme elevation. In monitored psychiatric protocols with moderation in total exposure, these problems are uncommon but not theoretical. Clinics screen for urinary symptoms across a course and may check liver enzymes when dosing is extended.

Drug interactions play a real role. Benzodiazepines, especially at higher doses, can blunt response. If you rely on benzos for panic, your team can often taper gently or adjust timing on dosing days to make space for ketamine’s mechanism. SSRIs, SNRIs, bupropion, and mirtazapine are generally safe to continue. Lithium has been used concurrently without clear safety signals in standard psychiatric dosing. Stimulants can add to cardiovascular load, so clinicians watch vitals more closely. MAOIs are rare today but call for specialist input if present. With antipsychotics, experience is mixed. Some patients with bipolar depression on quetiapine or lurasidone do well; others seem to have reduced response. Decisions are individualized.

How ketamine compares with other rapid strategies

In a patient with bipolar disorder and recurrent suicidal crises, lithium remains the gold standard for reducing suicide risk over the long term, with benefits that show up regardless of whether mood fully stabilizes. Clozapine shows robust anti suicidal effects in schizophrenia and schizoaffective disorder. Electroconvulsive therapy remains the fastest acting antidepressant in severe melancholic or psychotic depression, particularly when refusal to eat and drink or catatonia is present. Ketamine fits a different niche. It is quicker to access than ECT in many settings, it does not require anesthesia, and it can work within hours. When the goal is to create a near term reduction in suicidal pressure while building a longer plan, it is an excellent tool for many, not all.

Psychotherapy remains central. EMDR therapy, trauma therapy, and structured PTSD therapy protocols often become more doable after ketamine, when hyperarousal and intrusive loops quiet down. Couples therapy can support means restriction, communication during flashpoints, and reestablishing routines that protect sleep and sobriety. None of these replace medication when needed, but the combination tends to outperform any single element.

Access, cost, and what to expect administratively

Esketamine is available only through certified clinics. Visits run longer because of mandated observation. Insurance coverage has improved, especially under the indication for acute suicidal ideation or behavior, but authorizations and co pays vary widely. Patients should expect clinic staff to handle prior authorizations, but the process may take a week or more.

Intravenous racemic ketamine is almost always self pay in the United States. Per infusion fees often range from about 350 to 800 dollars, with regional variation. A full induction series of six infusions is a meaningful investment. Some out of network benefits can offset costs. Because protocols differ across clinics, ask in detail about monitoring, integration support, and coordination with your therapist and prescriber.

Home ketamine lozenges have spread through telehealth companies. While they can help some patients with chronic depression and anxiety under careful supervision, they are not the right tool for acute suicidal crises. The risk calculus shifts when someone is alone with a dissociative medication and intense suicidal thoughts. In office dosing with monitoring is the safer standard for this population.

A brief example from practice

A 34 year old teacher with recurrent major depression arrived in clinic after three months of daily suicidal thoughts and one prior overdose in college. She slept four hours a night, ruminated for hours, and had cut off friends. SSRIs, an SNRI, and augmentation with aripiprazole had each helped partly in the past, but this episode slammed through them. We admitted her voluntarily to a partner hospital for two days to stabilize and plan. She began esketamine in the hospital, then continued as an outpatient twice weekly.

By the second week she described a shift: “I can tell the thought is there, but it feels quieter and further away.” Sleep rose to six hours with fewer midnight awakenings. We coordinated with her therapist to restart trauma focused sessions. She agreed to let her sister hold onto extra medications and to text her safety plan nightly. After six sessions, her ideation had moved from daily and vivid to occasional and fleeting. We spaced treatments to weekly, added mirtazapine for sleep, and built routines for food, walking, and graded return to work. This was not a storybook cure. She had two tough days in week four and texted her sister to come over. That, to me, was success in the currency that matters.

When ketamine is the wrong door

If someone has a specific plan, access to lethal means, and intent they cannot set aside, the right setting is an emergency department or inpatient unit where 24 hour monitoring and immediate intervention are available. Ketamine may still be part of the hospital treatment, but it should not be started in an outpatient clinic when the floor is dropping out beneath a person. People who cannot consent, who are intoxicated, or who have unstable vital signs also need a different path first. The 988 Suicide and Crisis Lifeline exists for the gap between clinic hours and catastrophe. Families should save it in their phones, just as they do for pediatric fever questions and roadside assistance.

Integration and aftercare that make the benefit last

The most consistent mistake I see is treating ketamine as an isolated event. The brain is most plastic in the days following. That is the time to press into behavioral changes and therapy. Schedule a psychotherapy session within 3 to 5 days of each dose early on. Revisit means restriction at each visit, since improvement can ebb and flow. Normalize setbacks. They are data, not failure.

A compact aftercare plan helps patients translate insight into safety:

Book therapy sessions to align with the first 2 to 4 ketamine visits. Keep a brief daily log of suicidal intensity, sleep hours, and one action that supported safety. Share a written safety plan with one trusted person and review it weekly. Limit alcohol and cannabis, which can worsen rebound anxiety and sleep. Reassess other medications at the end of an induction series to extend gains.

Final thoughts for clinicians and families

Ketamine therapy is not magic, and it is not a last resort reserved for the edge of a cliff. It is a tool with a unique profile that can lower suicidal intensity within hours, offering a real chance to avert tragedy while the slower work of recovery unfolds. Using it well means honoring its speed and its limits. It means pairing medical monitoring with human presence, symptom scales with direct questions, and neurobiology with the lived patterns that make a week survivable.

When a person who could not sleep longer than two hours finally goes back to bed at 1 a.m. Without assaultive images, that small victory can cascade. When a couple practicing de escalation in therapy can use the afterglow of a ketamine session to try a new script, that can become a habit. When a trauma memory that always flooded the system can be revisited in EMDR therapy with less collapse, the future gets wider. Those are the changes that keep people alive. Ketamine therapy, used thoughtfully, helps them begin.